These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 3400266)
21. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022 [TBL] [Abstract][Full Text] [Related]
22. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347 [TBL] [Abstract][Full Text] [Related]
23. The dose-dependent fate of 1,4-dioxane in rats. Young JD; Braun WH; Gehring PJ J Environ Pathol Toxicol; 1978; 2(2):263-82. PubMed ID: 739213 [TBL] [Abstract][Full Text] [Related]
24. Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in F344 rats and B6C3F1 mice. Dill JA; Lee KM; Bates DJ; Anderson DJ; Johnson RE; Chou BJ; Burka LT; Roycroft JH Toxicol Appl Pharmacol; 1998 Dec; 153(2):227-42. PubMed ID: 9878593 [TBL] [Abstract][Full Text] [Related]
25. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs. Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117 [TBL] [Abstract][Full Text] [Related]
26. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine. Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467 [TBL] [Abstract][Full Text] [Related]
27. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. Nicolazzo JA; Nguyen TT; Katneni K; Steuten JA; Smith G; Jarrott B; Callaway JK; Charman SA J Pharm Pharmacol; 2008 Feb; 60(2):171-8. PubMed ID: 18237464 [TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics of ethosuximide enantiomers in the rat. Mifsud J; Collier PS; Millership JS Biopharm Drug Dispos; 2001 Mar; 22(2):83-9. PubMed ID: 11745910 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species. Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572 [TBL] [Abstract][Full Text] [Related]
31. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism. Bachmann KA; Nunlee M; Martin M; Schwartz J; Jauregui L; Forney RB Xenobiotica; 1990 May; 20(5):537-47. PubMed ID: 2112290 [TBL] [Abstract][Full Text] [Related]
32. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. Boothe DM; Perkins J J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278 [TBL] [Abstract][Full Text] [Related]
33. Use of MULTDOS for pharmacokinetic analysis of ethosuximide data during repetitive administration of single or divided daily doses. Colburn WA; Gibaldi M J Pharm Sci; 1978 Apr; 67(4):574-5. PubMed ID: 641778 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic properties of ethosuximide in monkeys. II. Chronic intravenous and oral administration. Patel IH; Levy RH Epilepsia; 1975 Dec; 16(5):717-30. PubMed ID: 816645 [TBL] [Abstract][Full Text] [Related]
35. Kinetics of a carbamazepine-ethosuximide interaction. Warren JW; Benmaman JD; Wannamaker BB; Levy RH Clin Pharmacol Ther; 1980 Nov; 28(5):646-51. PubMed ID: 7438684 [TBL] [Abstract][Full Text] [Related]
37. Use of three probes to assess the influence of sex on hepatic drug metabolism. Bachmann KA; Schwartz J; Jauregui L; Sullivan TJ; Martin M Pharmacology; 1987; 35(2):88-93. PubMed ID: 3628465 [TBL] [Abstract][Full Text] [Related]
38. The effects of cobalt chloride, SKF-525A, and N-(3,5-dichlorophenyl)succinimide on in vivo hepatic mixed function oxidase activity as determined by single-sample plasma clearances. Bachmann KA; Madhira MS; Rankin GO Xenobiotica; 1992 Jan; 22(1):27-31. PubMed ID: 1615705 [TBL] [Abstract][Full Text] [Related]
39. Quantification of urinary excretion of ethosuximide enantiomers and their major metabolites in the rat. Mifsud J; Millership JS; Collier PS; Morrow R; Hamilton JT; McRoberts WC Biopharm Drug Dispos; 2001 Apr; 22(3):129-36. PubMed ID: 11745915 [TBL] [Abstract][Full Text] [Related]
40. Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration and measurement. Mehvar R Pharm Res; 1991 Mar; 8(3):306-12. PubMed ID: 2052516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]